Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loa…
A Breakthrough for CML and Cancer TreatmentIn May 2001 – exactly 20 years ago – Novartis received approval from the US Food and Drug Administration (FDA) for the first targeted therapy for cancer, known as a tyrosine kinase inhibitor (TKI). This was a …
EMPATHY global multi-center Phase 2 – 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalizationThe study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700…
Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes (MDS). Fast track designation facilitates the development and expedites the review of drugs…
Who would have thought that an ancient Chinese herbal remedy would one day become the panacea for malaria? Sweet wormwood (Artemisia annua) was indeed used in traditional Chinese medicine for more than 2 000 …
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenaryNew Kisqali (ribociclib)* over…
Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needsKundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, …
Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malari…
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wai…
Today is World Asthma Day, when people across the asthma community come together to raise awareness of the challenges being faced by millions of people living with asthma, their families, friends and caregivers. Asthma is a common condition, affecting …